T etralogy of Fallot (TOF) is the most common form of cyanotic heart disease, with an incidence of 4 of 10 000 live births. 1 Surgical repair for TOF was first reported in 1954 for a cohort of 106 patients, with 30-year survival of 77%. 2 Longterm outcome data for patients with repaired TOF have been derived from single-center series, typically from tertiary referral centers, [3] [4] [5] [6] with results largely influenced by the center's surgical experience 7 or from non-US cohorts leveraging national health registries. [8] [9] [10] These reports are not representative of the survival experience of TOF patients in the United States owing to selection biases, differences in treatment strategies, techniques, or variation in population or health care systems. The Pediatric Cardiac Care Consortium (PCCC) is the oldest and one of the largest clinical registries for interventions for congenital heart disease in the United States.
11-13 Linkage of the PCCC to the registries of the National Death Index (NDI) and the Organ Procurement and Transplantation Network (OPTN) extends the follow-up time of PCCC-enrolled persons for major outcomes with nearly 90% sensitivity and almost 100% specificity for death and transplant events. 14, 15 In this study, we used the linked PCCC-NDI-OPTN data set to evaluate longterm transplant-free survival and causes of death (COD) of a large multicenter US-based cohort following TOF repair.
Methods
This is a retrospective cohort study enriched with prospective data from the NDI and OPTN. The OPTN includes data on all donor candidates, wait-listed candidates, and transplant recipients in the United States. The Health Resources and Services Administration and US Department of Health and Human Services provide oversight to OPTN contractors. The study was approved by the institutional review boards of Emory University, University of Minnesota, and the NDI and OPTN registries. Patient consent was not obtained owing to the retrospective nature of the study.
Cohort Selection
We queried the PCCC for patients who underwent repair for simple TOF (ie, excluding pulmonary atresia, absent pulmonary valve, or atrioventricular canal). Repair was defined as ventricular septal defect closure and right ventricular outflow tract (RVOT) reconstruction. We used PCCC surgical codes to determine the surgical treatment, dividing the cohort into 2 groups; those who underwent primary repair and those who underwent staged approach with initial palliative shunt. Other inclusion criteria included repair before age 21 years, US residency, surgery performed at a US center, and available full set of identifiers to allow reliable linkage with the NDI/OPTN registries. We included all patients with TOF repair after January 1, 1982, provided the first palliative procedure (shunt) was performed after January 1, 1980 . Patients enrolled in the PCCC after April 15, 2003 , lacked direct identifiers owing to implementation of stricter Health Insurance Portability and Accountability Act of 1996 rules and were excluded. Patients with in-hospital mortality after undergoing TOF repair as primary or staged approach were separated from the long-term survival cohort.
Data Collection
Variables for analysis included sex, age at repair (infancy, 1-5 years, and ≥5 years), era of TOF repair by decade (1982-1989, 1990-1999, and 2000-2006) , surgical staging (primary vs staged repair), pulmonary valve approach (valve sparing vs non-valve sparing), and presence of a genetic condition such as chromosomal abnormality or DiGeorge syndrome (clinical criteria or documented 22q11.2 deletion). Prior shunt palliation was determined by querying the PCCC for surgery consistent with any systemic-to-pulmonary shunt (eg, BlalockTaussig). Type of surgical RVOT reconstruction and valve approach were assigned by the respective PCCC surgical codes; manual review of operative notes was performed when ambiguity existed.
Ascertainment of Death or Transplant Events
Death or transplant events were ascertained from the PCCC and by matching to NDI and OPTN records through December 31, 2014. 14 Records submitted to the NDI and OPTN included first name, middle initial, surname, date of birth, sex, state of last known residence, and state of birth. Those with inadequate identifiers could not be reliably linked and were excluded.
Causes of Death
The NDI defines underlying COD as the disease or injury that initiated the train of events leading directly to death or the circumstances of the incident of violence that produced fatal injury. 16 Other conditions on the death certificate are considered contributing COD. Information about underlying and contributing COD for each confirmed death was supplied by NDI-Plus, as reported on death certificates, and was used to assign deaths into one of several categories. Congenital heart disease was assigned as the underlying COD when TOF was listed as the primary condition in the sequence of events. Other cardiovascular disorders (CVD) were assigned as the COD when such conditions were reported without reference to underlying CHD. Additional categories included other congenital noncardiac malformations, respiratory diseases, infections, neoplasms, external causes (ie, injury, poisoning, or suicide), and miscellaneous causes.
Key Points
Question What are the patient and surgical characteristics affecting long-term transplant-free survival following surgical tetralogy of Fallot repair?
Findings In this cohort study of 3283 patients with tetralogy of Fallot, survival following complete repair was 98.6%, 97.8%, 97.1%, 95.5%, and 94.5% for 1-year, 5-year, 10-year, 20-year, and 25-year survival, respectively, with an early peaking hazard of mortality shortly after repair. Statistically significant associations with decreased long-term survival included staged repair, non-valve-sparing operation, repair in earlier surgical era, and presence of a genetic abnormality.
Meaning Overall long-term transplant-free survival in repaired tetralogy of Fallot is excellent, with several factors affecting survival, some of which may be modifiable such as planning of the surgical strategy.
Statistical Methods
Descriptive statistics were calculated for variables of interest and included means with standard deviations, medians with interquartile ranges (IQR), or counts and percentages. In a univariate analysis, hospital survivors and nonsurvivors were compared using χ 2 tests (or a Fischer exact test when expected cell counts were <5) for categorical data and Wilcoxon rank-sum tests for continuous data. Multivariable logistic regression was used to identify risk factors associated with mortality following TOF repair. Transplant-free survival following hospital discharge for TOF repair was treated as a time-dependent outcome and modeled parametrically. Parametric probability estimates for this time-dependent outcome used models based on multiple overlapping phases of risk using the PROC HAZARD function available with SAS (SAS Institute Inc). The HAZARD procedure uses maximum likelihood estimates to resolve risk distribution of time to event in up to 3 phases of risk (early decreasing or peaking hazard, constant hazard, and late increasing or decreasing hazard). An early steep hazard followed by a late increasing hazard was found for the primary outcome of transplant-free survival. As a result, a 2-phase (early and late) survival parametrization was used to estimate survival. Therefore, early and late phase survival was defined as less than 6 years and at least 6 years following repair, respectively.
In these models, maximum likelihood estimates were iteratively calculated using nonlinear optimization-based algorithms. Smoothed survival curves were generated using the HAZPRED procedure in SAS. The PROC HAZPRED computes predictions for the survivorship and hazard functions along with their confidence limits. To identify risk factors associated with death/transplant following TOF repair, parametric survival models were constructed using 1 risk factor at a time. Multivariable models used forward selection of variables significant at the 0.2 level in univariate analysis. Effects of covariates on the likelihood of death/transplant are presented as hazard ratios (HRs) with 95% confidence intervals. Risk factors are presented separately for the early-phase and late-phase survival periods. Statistical analyses were conducted using SAS, version 9.4 (SAS Institute). Statistical significance was assessed at the .05 level unless otherwise noted, and all P values were 2-sided.
Results
There were 3894 total patients with simple TOF who underwent repair and met inclusion criteria. Three thousand one hundred sixty-eight underwent primary repair, while 726 had a staged approach with initial shunt followed by repair. During the study period, there was a trend toward earlier primary repair (aged <1 year), but otherwise, there was no significant difference in the use of staged vs primary repair or between valve-sparing vs non-valve-sparing strategies (eTable 1 in the Supplement).
There were 161 in-hospital deaths following surgery: 47 in the staged group and 114 in the primary repair group. Following repair, 3733 were discharged alive. Of these, 3283 patients had direct identifiers available and compose the cohort submitted to the NDI/OPTN, while 450 had insufficient identifiers and were excluded. There were no significant differences in the clinical characteristics of patients with TOF with and without identifiers (data not shown).
14 A STROBE-style diagram detailing cohort selection is included (eFigure 1 in the Supplement). Over a median follow-up period of 18.5 years (maximum, 33 years; IQR, 14.6-22.4 years), 145 deaths (3 following transplant) and 5 transplants occurred. The median age at death was 1.0 years (IQR, 0.6-2.1 years), with range 3 days to 19.7 years.
In-Hospital Mortality After TOF Repair
In-hospital mortality following TOF repair was 4.1% and occurred more commonly in infants, patients weighing less than 2.5 kg (proxy for prematurity) at repair, patients with prior shunt palliation, in earlier surgical eras (1982-1989 and 1999-2000) , and concurrent genetic syndrome ( Table 1) . After adjustment covariates, these factors remained significantly associated with increased risk of perioperative death (eTable 2 in the Supplement).
Long-term Survival After Complete TOF Repair
Overall long-term transplant-free survival following discharge alive after TOF repair was 98.6%, 97.8%, 97.1%, 95.5%, and 94.5% at 1, 5, 10, 20, and 25 years after repair ( Figure 1A ). The overall hazard of mortality or transplant in patients with simple TOF following repair showed an early steep hazard followed by a late, increasing hazard. As a result, a 2-phase survival parametrization was used to estimate transplant-free survival ( Figure 1B) : (1) an early postdischarge period with high hazard that decreases rapidly before reaching a minimum at 6 years following discharge and (2) a late period with low but steadily increasing hazard beyond 6 years following repair and with acceleration around 20 years postoperatively.
Factors Associated With Long-term Mortality
Stratified transplant-free survival patterns ( Figure 2A -F) demonstrated a rapid decrease in survival in the first 2 years following repair for those undergoing staged repair and non-valve-sparing repair, resulting in a long-term survival advantage over single-stage and valve-sparing approaches throughout the subsequent 20 years ( Figure 2C and D, respectively). In addition, the survival of those with a genetic abnormality was significantly disadvantaged compared with those without during the whole postoperative study period ( Figure 2E ). A more rapid early mortality was noted for those who underwent repair in the earliest era, but long-term survival was similar across all eras ( Figure 2F ). A unique group of patients included within the non-valvesparing group were those repaired with a right ventriclepulmonary artery conduit (n = 88). This group experienced a higher number of deaths 2 to 4 years after TOF repair compared with the other non-valve-sparing patients, but the number of events is too small to detect a significant difference in long-term survival (eFigure 2 in the Supplement).
Univariate analysis revealed several factors associated with increased late mortality following TOF repair (eTable 3 in the Supplement). In the early postoperative phase (<6 years), these factors included staged vs primary repair (HR, 3.45; 95% CI, 2.02-5.89), non-valve-sparing vs valve-sparing operation (HR, 4.56; 95% CI, 1.86-11. 20) , and presence of a coexisting genetic condition (HR, 3.81; 95% CI, 2.14-6.79). Genetic abnormality was the only factor associated with higher risk for premature mortality in the later phase (>6 years) (HR, 4.41; 95% CI, 2.59-7.52).
After covariate adjustment, staged surgical strategy (HR, 2.68; 95% CI, 1.59-4.49), non-valve-sparing approach (HR, 3.76; 95% CI, 1.53-9.91), repair in the earliest surgical era (HR, 2.31; 95% CI, 1.06-5.03), and coexisting genetic condition (HR, 3.64; 95% CI, 2.05-6.47) were all linked to increased mortality in the early period ( Table 2 ). In the later phase, presence of a genetic abnormality was the only association with increased risk of death (HR, 4.41; 95% CI, 2.62-7.44).
Causes of Death
Most deaths among those surviving TOF repair were directly (n = 63 [43.5%]) or indirectly (n = 76 [52.4%]) attributed to TOF (Table 3) , with a variety of contributing CVDs including arrhythmia (n = 12 [8.3%]), cardiac arrest (n = 34 [23.5%]), and congestive heart failure (n = 26 [17.9%]) (eTable 4 in the Supplement). Other common CODs include other CVD such as myocardial ischemia and stroke, other congenital anomalies, and external causes (death from unintentional injury or suicide).
Cardiovascular disease, without reference to TOF, accounted for 15.2% of deaths (n = 22), while 41.4% (n = 60) were assigned to a non-CHD/non-CVD condition. The most frequent CODs outside CHD/CVD were external causes (n = 16 [11%]), other medical causes (n = 19 [13.1%]), other congenital anomalies (n = 10 [6.9%]), and neoplasms (n = 5 [3.5%]). Review of COD by surgical era did not reveal any significant differences (data not shown).
Discussion
Tetralogy of Fallot is a common form of cyanotic CHD that has been repaired for the past 60 years with evolving treatment approaches. 2 The number of adult survivors of TOF repair is rapidly increasing. 8, 17 While there have been many studies evaluating short-term and midterm outcomes in TOF, data about factors putting patients at risk for remote death are scarce, primarily limited to single-center or international registry cohorts.
3-10, 15, 18 To our knowledge, this study describes the largest multicenter cohort of patients with repaired TOF in the United States, with more than 25 years of follow-up after surgical repair. The study of long-term outcomes by various surgical strategies in relation to era and patient-level factors provides opportunities to assess treatment decisions affecting the long-term outcomes of patients with repaired TOF. Survival in the PCCC cohort exceeds 94% at 25 years after TOF repair, which is comparable with single-center US and international registry studies reporting 30-year survival between 80% and 98%.
7-9, 17 The large size of the PCCC cohort coupled with a long period of follow-up after linkage with national registries allowed us to provide a nuanced report on the factors associated with long-term survival. 
Patterns of Long-term Survival After TOF Repair
Patients with repaired TOF have a biphasic hazard for mortality, an early steep hazard during the first 4 years after TOF repair, and a late hazard with a slow increase in mortality after 6 years and acceleration 20 years later. Earlier surgical eras had an inverse association with the chances of survival in the early postoperative phase, indicating higher residual postoperative morbidity, which is consistent with previous reports. 8, 9, 17, 19 In the PCCC cohort, the late-phase survival and COD have not substantially changed over time. These findings suggest that residual morbidity remains a major factor affecting survival of these individuals despite improvements in acute and midterm treatment. Not surprisingly, coexistence of a genetic anomaly remains a risk factor for mortality in both early and late postoperative phases. This indicates that at least some of the residual morbidity can be explained by coexisting genetic abnormalities.
Staged repair and non-valve-sparing operation were both associated with increased early-phase hazard for death following repair, ultimately translating to worsened long-term survival. The choice between staged vs single-stage repair and between valve-sparing vs not may reflect nonmeasured covariables such as more severe underlying pathology or other comorbidities. Those undergoing initial palliation with a shunt may also have residual deleterious effects related to the initial palliative shunt (eg, pulmonary artery distortion, excessive pulmonary blood flow, and left heart overload). Patients with non-valve-sparing approach are exposed to higher likelihood for subsequent reoperation and perioperative complications. Potentially, pulmonary insufficiency associated with non-valve-sparing operation has an adverse association with early ventricular hemodynamics affecting survival.
There is also a trend toward increased mortality in the subgroup undergoing right ventricle-pulmonary artery conduit placement, at a time when procedures for an outgrown conduit are expected to take place, but the relatively small number of this group limits conclusions.
Mortality differences between staged and primary repair strategies have been inconsistent among multiple studies supporting each strategy. 18, [20] [21] [22] In regards to the use of valve vs nonvalve-sparing approach, prior studies detected no significant difference in long-term survival between patients treated with transannular patch (TAP) vs those with valve-sparing operation despite less valve replacements in the valve-sparing group. 23, 24 Because most of these studies are single-center, they
are not suitable to address the issue of center effect. The large number of participating centers in the PCCC allows us to leverage center variation in the TOF surgical strategy and compare the effectiveness of each strategy in a quasiexperimental design based on center and regional variation. In this regard, the lack of significant variation in the number of staged vs primary repairs and types of RVOT reconstruction between centers suggests these choices are less likely to be driven by centerrelated experience or level of expertise. Modifications aiming to preserve the infundibulum with a mini-incision have been described, hoping to confer longterm survival advantages. 25, 26 Reported midterm survival (97% at 7 years of postoperative follow-up) with this strategy is similar to the outcomes in our study, and longer follow-up will be needed to determine whether a positive effect on morbidity or mortality exists with this modification.
Causes of Death After TOF Repair
Most deaths after TOF repair were directly or indirectly associated with TOF and were reported as sudden death, arrhythmia, and congestive heart failure. The rates of sudden death and heart failure in our cohort are similar to those reported in other studies. 9, 18 The CODs in our cohort were similar to those reported in a study from Taiwan, 10 with the exception of the high incidence of deaths from unintentional injury and suicides, which were not confirmed in our cohort. This difference may be associated with local factors and the relatively small number of patients and death events in the Taiwanese study, limiting generalization for reported COD in categories with relatively rare events. 
Strengths and Limitations
The primary strengths of our study are the large number of patients and participating centers as well as the length of follow-up. However, our study does have limitations as well. The PCCC registry lacks information regarding potentially important contributors to long-term mortality such as presurgical variables affecting choice of surgical strategy, frequency and type of subsequent procedures, medications used, and socioeconomic variables. In addition, there is limited information regarding the status of the RVOT following surgery. There are also important limitations in the use of NDI for ascertainment of COD as highlighted by some comparison studies of assigned COD between NDI-based vs direct review methods. For example, such a study 27 in a cohort of patients with coronary heart disease concluded that sensitivity and positive predictive value for the NDI-assigned coronary heart disease COD were relatively weak, while specificity and negative predictive value were strong. More specifically, NDI data tended to overestimate coronary disease as the COD, especially in older patients with multiple comorbidities. 27 Extrapolating to our study, it is possible that some of the deaths in the TOF population may have been misclassified. Nonetheless, attributed COD based on NDI data have been shown to correlate well to other methods of death ascertainment including case-by-case review by nosologists or review with state-level death records with discordance rates less than 10%.
28,29
Conclusions
Our study provides important information about the longterm outcomes of patients with repaired TOF in the United States. The data highlight the shortcomings of early repair, staged, and non-valve-sparing approaches in the early period following repair. Long-term transplant-free survival beyond the first 6 years following repair is excellent and influenced primarily by the coexistence of an associated genetic condition. Within the 25-year follow-up period, most deaths were associated with the underlying diagnosis of TOF and mediated by arrhythmias and congestive heart failure. Continuous surveillance of this cohort is important in identifying additional risks resulting from the interaction of underlying conditions with cardiovascular morbidities expected with aging. Author Contributions: Drs Kochilas, the senior author, and McCracken, the biostatistician performing the analysis, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The evolution of surgery in tetralogy of Fallot (TOF) reflects the development of congenital cardiac surgery in general. Initially, TOF surgeries offered palliation: systemic-topulmonary shunts that would improve pulmonary blood flow and raise oxygen saturations at the expense of continued cyanosis and a volume load on the left ventricle. Systemic-to-pulmonary artery shunts arising from the subclavian artery (Blalock-Taussig shunts) or aorta (Waterston and Potts shunts) showed very different complications over long-term follow-up. Once cardiopulmonary bypass allowed complete repair of TOF, strategies were developed to optimize different issues that were identified.
Initially, patients typically underwent complete repair after 12 months, often after placement of a palliative shunt allowed somatic growth in small infants who developed cyanosis at an early age. The transannular patch (TAP) technique allowed primary repair to be performed at younger ages and in patients with smaller body sizes. Transannular patch repair uses an incision from the right ventricle across the pulmonary valve into the main pulmonary artery. Through this incision, the ventricular septal defect is closed with a patch, and another patch is placed to enlarge the outer surface of the pulmonary outflow from the right ventricular outflow tract, across the pulmonary annulus and into hypoplastic main and branch pulmonary arteries. Advocates of this approach believe that primary early infantile (even neonatal) TAP repair avoids potential neurological complications of cyanosis and the risk of so-called hypercyanotic tet spells, as well as possibly improving development of the pulmonary vasculature. However, use of a TAP causes free pulmonary regurgitation and a large volume load on the right ventricle. 1 In contrast, other groups emphasized a pulmonary valvesparing transatrial-transpulmonary repair, which they postulated would better preserve right ventricular function. 2 They advocated shunt palliation of infants who are symptomatic, with later repair allowing more frequent preservation of the pulmonary valve. 
